Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
Publikation: Beitrag in Fachzeitschrift › Übersichtsartikel (Review) › Beigetragen › Begutachtung
Beitragende
Abstract
The prevalence of nonalcoholic fatty liver disease (NAFLD), recently also re‐defined as metabolic dysfunction associated fatty liver disease (MAFLD), is rapidly increasing, affecting ~25% of the world population. MALFD/NAFLD represents a spectrum of liver pathologies including the more benign hepatic steatosis and the more advanced non‐alcoholic steatohepatitis (NASH). NASH is associated with enhanced risk for liver fibrosis and progression to cirrhosis and hepatocellular carcinoma. Hepatic stellate cells (HSC) activation underlies NASH‐related fibrosis. Here, we discuss the profibrogenic pathways, which lead to HSC activation and fibrogenesis, with a particular focus on the intercellular hepatocyte–HSC and macrophage–HSC crosstalk.
Details
Originalsprache | Englisch |
---|---|
Aufsatznummer | 6996 |
Fachzeitschrift | International journal of molecular sciences |
Jahrgang | 23 |
Ausgabenummer | 13 |
Publikationsstatus | Veröffentlicht - 1 Juli 2022 |
Peer-Review-Status | Ja |
Externe IDs
PubMed | 35805998 |
---|
Schlagworte
ASJC Scopus Sachgebiete
Schlagwörter
- fibrosis, hepatic stellate cells, hepatocyte, macrophage, metabolic associated fatty liver disease, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis